Results 221 to 230 of about 318,820 (346)

Hyperthyroid heart disease: Diagnostic and therapeutic aspects [PDF]

open access: yes, 1990
Reinwein, Dankwart   +2 more
core   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

From Resistance to Relief: IV Levothyroxine in Refractory Hypothyroidism Management. [PDF]

open access: yesClin Case Rep
Amro M   +6 more
europepmc   +1 more source

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab

open access: yesCancer Science, EarlyView.
This study highlights the importance of germline genetic markers in predicting severe trAEs caused by nivolumab. Our findings support their potential to guide personalized immunotherapy and improve treatment safety and efficacy in advanced ccRCC and other cancers.
Tokiyoshi Tanegashima   +26 more
wiley   +1 more source

The role of hypothyroidism in cirrhosis pathogenesis: A retrospective cohort study and multi-omics integration analysis. [PDF]

open access: yesPLoS Genet
Yang Z   +14 more
europepmc   +1 more source

Liver Injury Induced by Levothyroxine in a Patient with Primary Hypothyroidism

open access: diamond, 2007
Tomotaka Kawakami   +13 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy